This site complies with the HONcode standard for trustworthy health information:
150 153rd Ave,
Madeira Beach, FL 33708
Diabetic Cystic Fibrosis Patients Effected by "Superbug"
By Daniel H. Rasolt
Posted: Sunday, March 22, 2009
(Defeat Diabetes® News) -- A common
procedure to treat cystic fibrosis (CF), in which a specific type of sugar is
inhaled into the lungs, might lead to dangerous complications, especially for
diabetics. A bacteria, known as burkholderia cepacia complex (Bcc),
appears to create further mucus buildup for CF patients as a result of this
procedure, and has been labeled a "superbug."
Cystic fibrosis is
characterized by the buildup of easily infected mucus within the lungs. Certain
bacterias, such as Bcc, are responsible for infection and further mucus buildup,
which is extremely difficult to treat. Specifically, Bcc has been observed to
create a very thick substance, exopolysaccharide (EPS), that worsens lung
function for CF patients.
This buildup of EPS as a result of Bcc
infection appears to often be a byproduct of a common treatment that utilizes
the sugar mannitol. In this treatment, mannitol is inhaled into the lungs, which
has the effect of "attracting moisture," and making it easier to clear out the
dangerous mucus. Unfortunately, with the observation of Bcc buildup, this
treatment may have to be curtailed or abandoned.
Speaking of the dangers
of Bcc, study author Professor John Govan says, "Burkholderia make other
superbugs look like wimps. They not only have larger genomes (hence genetic
potential) and are resistant to almost all antibiotics, they can even use
antibiotics such as penicillin as a nutrient."
It's not known exactly why
Bcc results from mannitol treatment, but it's been further suggested that
because of the increased buildup of sugar in the body, CF patients with diabetes
are more susceptible to Bcc infections. This potential explanation is of
particular concern because there is an established link between CF and diabetes.
Commenting on the recent research, Dr. David Reid explains that "CF-related
diabetes affects almost one-third of adults with CF."
This research could
create a fair amount of confusion and uncertainty in how to treat CF patients,
especially the one-third who have diabetes. Mannitol treatment, in some cases,
might just be the progenitor of a dangerous cycle. Mannitol thins out the mucus
(including that created by Bcc, occasionally), but with Bcc being a byproduct,
further, potentially more dangerous, mucus, is created. Further research,
especially pertaining to mannitol treatments in diabetics, is
Source: Defeat Diabetes Foundation: Govan, John. Reid, David. Stilwell, Diane. Microbiology news release. March 2009.
Daniel H. Rasolt writes for Defeat Diabetes® News. Read more of his original content articles.
Copyright © 2009 Defeat Diabetes Foundation, Inc. All rights reserved.
Send your unopened, unexpired diabetes testing supplies to:
Defeat Diabetes Foundation
150 153rd Ave, Suite 300
Madeira Beach, FL 33708
Analyze nutrition content by portion